UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Presentations
Impact of primary (1˚) tumor location on overall survival (OS) and
progression-free survival (PFS) in patients (pts) with metastatic
colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).
Authors*: Alan P. Venook, Donna Niedzwiecki, Federico Innocenti, Briant Fruth,Claire Greene, Bert H. O’Neil,
James Edward Shaw, James Norman Atkins, Laura E. Horvath, Blase N. Polite, Jeffrey A. Meyerhardt,
Eileen Mary O’Reilly, Richard M. Goldberg, Howard S. Hochster, Charles David Blanke, Richard L. Schilsky,
Robert J. Mayer, Monica M. Bertagnolli, Heinz-Josef Lenz
Abstract #: 3504
Presentation Date/Time: Sunday, June 5: 8:00 – 11:00AM
Location: Hall B1
Oral Abstract Session: Gastrointestinal (Colorectal) Cancer
Citation: J Clin Oncol 34, 2016 (suppl; abstr 3504)
Venook Research Interests: Dr. Alan Venook is a nationally renowned expert in colorectal and liver cancers at
the UCSF Helen Diller Family Comprehensive Cancer Center. He is highly regarded for his expertise in the
effective use of the newest approaches and therapies to the treatment of colorectal cancer, as well treating
primary and metastatic tumors to the liver. Dr. Venook has chaired and/or authored six major studies within
the cooperative groups and he now Chairs the GI Committee of the Alliance for Clinical Trials in Oncology
(formerly CALGB.)
http://cancer.ucsf.edu/people/profiles/venook_alan.3698
*UCSF authors in bold
62